
feb pm et
summari compani develop research tool instrument large-scal analysi
genet variat function
price-to-earnings oper ep
advanc highli competit marketplac
better capit competitor rel new industri
oper heavi concentr
client depend govern fund
ep estim base cfra oper earn histor
earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
contribut helix rise
billion robust consum servic
sale well strong demand novaseq
follow rise januari
introduc novaseq
novaseq think could reduc
cost sequenc
novaseq believ ship
system client transit
hiseq look continu robust
order flow hiseq replac cycl
begin interest commerci
client grow think upgrad cycl
regulatori reimburs decis
see oper margin
still
due increas headcount
invest helix compani form
warburg pincu sutter hill collect
store consum genom data well
grail compani focus cancer screen
blood test
see ep benefit
tax reform dilut helix
think maintain market lead
posit genet sequenc deserv
premium valuat believ share
trade ep estim well
peer near mid-point
five-year histor rang
attract valu see sale earn
growth moder
low-to-mid teen still view
current growth attract better
peer growth see continu gain
market share amid expans within
appli market continu solid demand
research market aid novaseq
sale think goal annual
sale growth next three year
challeng expect increas
instal base drive higher margin
five-year goal sale
commerci client well
risk recommend target price
would soft next-gener sequenc
target
above-p ep estim
within five-year rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop research tool large-scal analysi genet variat
function analyz understand genet variat function critic develop
person medicin key goal genom genet variat account mani physic
differ among human hair color height eye color variat also import
medic consequ includ predisposit diseas differenti respons drug
tool assist research process billion test necessari convert raw genet data
medic valuabl inform improv drug therapi custom diagnos treatment
potenti cure diseas compani instrument system consum design simplifi
genet analysi acquisit solexa inc acquir proprietari sequenc
synthesi sb technolog incorpor sequenc instrument system
use perform rang nucleic acid analys dna rna larg number sampl
determin variat scientist analyz variat potenti consequ human
anim plant microorgan method studi genet variat biolog
function includ sequenc single-nucleotid polymorph snp variat singl
posit nucleotid base dna sequenc genotyp copi number variat cnv analysi gene
express profil gene regul analysi
oper within two busi segment life scienc unit diagnost unit life scienc
research encompass studi live thing human anim plant virus
bacteria research perform govern univers pharmaceut biotechnolog
agrigenom laboratori around world scientist seek expand knowledg
biolog function life provid scientist necessari instrument tool
analysi molecular diagnost test design identifi biolog indic link
diseas drug metabol provid physician inform effect diagnos treat
monitor diseas condit
market profil sequenc gene express genotyp market rel new
technolog util market evolv rapidli compani within industri typic
limit histori commerci sale instrument system consum also may reli
genet sequenc inform contain public scientif databas throughout world
databas also rapidli expand evolv primari user technolog life scienc
pharmaceut compani includ mani academ govern institut
depend govern fund howev technolog continu advanc price point
declin appli market clinic diagnost industri increasingli util sequenc
instrument tool well diagnost test product develop advanc
discoveri made genet sequenc
competit landscap character competit landscap intens sever
larger better capit publicli trade compani well numer emerg privat compani
publicli trade compani includ thermo fisher scientif acquir main competitor life
technolog februari affymetrix agil follow purchas beckman coulter
amersham bioscienc subsidiari howev believ compani
sizabl instal system instrument may hold competit advantag emerg compani
instal system typic drive sale consum product transit one system
anoth also costli time-consum compani industri highli depend signific
 spend maintain abil develop new competit technolog larger compani
access greater resourc may advantag
februari acquir verinata health provid non-invas pre-nat diagnost test
includ test syndrom million januari acquir solexa inc slxa
develop genet analysi system primarili area whole genom re-sequenc per
share stock million term deal slxa sharehold receiv million
share base exchang ratio share stock issu share slxa
financi trend report first profit quarter fourth quarter see
continu profit despit expect higher oper cost consist increas sale
sinc incept sale rose consecut quarter second quarter
sale declin sequenti rose year-earli level sale growth driven
increas instal base-lead higher sale consumables-and robust uptak
new sequenc system sale aid acquisit increas million
billion adjust oper margin fluctuat adjust
ep increas
senior vice presid
oper product
strategi
counsel secretari
cfo senior vice-president
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
life scienc tool servic sub-industri
next month may congress
approv billion increas nation
institut nih fy budget
billion septemb
billion increas fy budget
increas contrast presid
trump call cut nih budget
billion billion fy fy
signific fund academ lab
turn account sale life
scienc tool compani averag
trump propos indic
administr prioriti actual fund
determin congress think
signific bipartisan support nih
believ congress disregard trump propos
cut nih budget nonetheless trump
propos budget creat uncertainti
may result project termin
cloud futur research project
view nih budget rose
billion billion
largest percentag increas sinc
includ billion stimulu fund
american recoveri reinvest act
arra
howev note mani life scienc
compani activ pursu initi
commerci non-academ govern
revenu base also see budget issu
europ result soft govern fund
decemb presid obama sign
centuri cure act law law
provid billion year
nation institut split
go cancer moonshot billion
fund precis medicin initi
billion fund brain initi
support alzheim diseas research
overal see mid-single-digit sale growth
emerg market
china remain robust growth region
grow double-digit rate help fuel
overal industri growth believ demand
strong begin moder
think research lab suffici
equip current need mani
equip compani also diversifi
product line increas sale
consum typic immun
budget constraint expand
area environment food
safeti agricultur growth
end-market expect robust
pharmaceut research
compani provid servic
pharmaceut biotech firm
contract research organ see
solid growth next month
view believ pharmaceut biotech
firm increasingli outsourc servic
think increas effici lower
cost also see increas strateg
 life scienc tool
 composit index year date
decemb life
rise composit
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
inc announc mark van oen name chief commerci
offic van oen previous illumina senior vice presid america
region subsequ name interim chief commerci offic late
chief commerci offic van oen respons world-wid sale
servic market report presid ceo franci
et cfra keep hold opinion share inc
rais target peer
next ep estim keep ep estim
rais ep vs line
estim sale rose solid growth consum
servic partial off-set declin instrument anticip
novaseq launch expect oper margin fell
headcount increas invest grail helix believ demand
novaseq next gener sequenc strong order /jeffrey
budget call cut nation institut nih budget
call elimin fogarti
intern center facilit collabor among
intern research surpris magnitud propos
cut nih budget rel flat past year
receiv increas along addit year
centuri cure act mani life scienc compani reli
nih-fund facil drive sale /jeffrey loo cfa
inc announc john thompson join
compani board director may bring extens
technolog leadership experi compani mr thompson execut
leadership experi includ serv chief execut offic role
symantec virtual instrument well year prior leadership
experi held senior role sale market softwar
develop gener manag america
et capit iq keep hold opinion share
inc lower target
peer revis ep estim
faster growth moder past year set ep estim
ep vs estim sale rose
gross margin fell oper margin fell
partli increas invest headcount grail helix instrument
sale fell see pickup new sequenc novaseq begin
ship guid sale growth ep
analyst research note compani news
et cfra reiter buy opinion share inc
rais target peer
ep estim set ep
vs ahead view sale rose robust
rise sequenc consum growth instrument novaseq
shipment high ship sinc launch
januari new client look anoth robust year
novaseq hiseqx client transit platform also
think use sequenc move rapidli commerci applic
et cfra reiter buy opinion share
thermo fisher scientif announc
deal enabl sell ion ampliseq technolog research
util next-gener sequenc platform sell
product name ampliseq continu
sell custom share rose significantli follow
announc deal two largest firm genet
sequenc space rais possibl partnership rais
target peer ep estim
inc announc aime hoyt head human resourc team ms
hoyt join senior vice presid chief peopl offic cpo
start januari respons lead aspect
compani hr strategi report ceo recent
chief offic rackspac
presid chief account offic princip account offic
purpos compani file secur exchang commiss
ms mcginni recent serv presid chief execut offic
director mad catz interact inc prior appoint presid
chief execut offic februari ms mcginni serv mad catz
inc announc gari guthart join compani
board director decemb dr guthart presid chief
execut offic dr guthart join intuit
surgic april serv chief execut offic sinc
et cfra rais opinion share buy
hold rais target
peer forward ep estim faster growth
ep vs ahead estim rais
ep estim sale rose
best growth rate sinc sale rose driven strong adopt
novaseq platform ship novaseq sinc launch
januari includ see continu robust growth
see client base expand includ previou benchtop custom /jeffrey
et cfra keep hold opinion share inc
rais target price above-p
forward ep estim within rang
ep vs ahead estim sale
rose driven strong demand novaseq sequenc consum
microarray receiv order novaseq sinc launch
januari order come hiseq replac cycl
look continu robust order flow hiseq replac cycl
begin interest commerci custom grow /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
